Implanet Reports Q3 2019 Revenue of €1.7 Million, Up 12% - Seite 2

Over the first 9 months of 2019, Implanet recorded revenue of €5.56 million, up 7% on the same period of 2018

JAZZ revenue totaled €3.57 million for the first 9 months of the year, up 10% on the €3.25 million recorded in 2018, driven by significant growth in the United States, where JAZZ sales continued to improve over the period to €1.78 million (+13%). Europe, excluding France, generated revenue of €0.61 million (+31%). In France, the bulk of the sales decline due to a shift in surgeries observed at the end of June has now been caught up on, with revenue totaling €1.19 million versus €1.22 million last year.

In total over the first 9 months of the year, across its three geographical regions Implanet sold 6,963 JAZZ units, up 6% by volume on the previous year (2018: 6,579 JAZZ units).

Knee activity recorded slight growth of 3%, with revenue of €1.98 million to end-September 2019. The period saw the first delivery to KICo Knee.

Key 2019 events to date:

- Signing of strategic partnership with SeaSpine, Inc., a wholly owned subsidiary of SeaSpine Holdings Corporation (NASDAQ: SPNE), to market the JAZZ range in the USA, the world’s biggest market for the treatment of spinal pathologies. This contract has an initial term of six years and includes minimum annual payments, significantly increasing market access in this region;

- JAZZ Cap FDA clearance, offering a unique and proprietary solution for securing pedicle screws in poor-quality bone. JAZZ Cap technology strengthens the offering of JAZZ products in the USA;

- Introduction of a €3.0 million convertible bond financing line with Nice & Green, with twelve monthly instalments of €250k from May 2019 to April 2020;

- Successful completion of the first JAZZ Cap surgical operations in the USA;

- The first deliveries of orders placed as part of the deployment of partnerships established with KICo Knee and SeaSpine, Inc.

Upcoming conferences Implanet will attend:

- EuroSpine, October 16^th to 18^th, 2019, Helsinki, Finland

- SOFCOT (French Society of Orthopaedic & Traumatological Surgery Congress), November 11^th to 13^th, 2019, Paris, France

- DWG German Spine Congress, November 28^th to 30^th, 2019, Munich, Germany

Next financial press release: 2019 annual revenue, on Tuesday January 21^st, 2020 (after market)

About Implanet

Founded in 2007, Implanet is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Implanet’s tried-and-tested orthopedic platform, which is based on perfect control over the traceability of its products, provides it with a proven ability to promote this innovation. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. Implanet employs 38 staff and recorded 2018 sales of €6.7 million. For further information, please visit www.Implanet.com. Based near Bordeaux in France, Implanet established a US subsidiary in Boston in 2013. Implanet is listed on Euronext Growth market in Paris. The Company would like to remind that the table for monitoring the equity line (OCA, OCAPI, BSA) and the number of shares outstanding, is available on its website: http://www.implanet-invest.com/suivi-des-actions-80